$EGRX on Be prepared for possible Growth
As Eagle Pharma Win Patent Decision for Bendeka, Court issued a favorable patent decision for Bendeka bendamustine hydrochloride injection, or bendamustine HCl , a liquid, low-volume and short-time 10-minute infusion formulation of bendamustine hydrochloride. So with that 
EGRX shares rose 23% to $63.25 in premarket trading. With ongoing evaluation of the efficacy and safety of the medicament, EGRX is showing a good and healthy growth at stock market.
EGRX shares rose 23% to $63.25 in premarket trading. With ongoing evaluation of the efficacy and safety of the medicament, EGRX is showing a good and healthy growth at stock market. 
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.